BRCA1 and cancer: The defective HR, and/or increased expression of genes involved in immune checkpoint suggest that BRCA1-deficient cancer should have higher sensitivity to immune checkpoint blockade (ICB), as these factors are associated with increased responses to the treatment23–26.